OFI Invest Asset Management Purchases 123 Shares of IQVIA Holdings Inc. $IQV

OFI Invest Asset Management increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 22.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 682 shares of the medical research company’s stock after acquiring an additional 123 shares during the quarter. OFI Invest Asset Management’s holdings in IQVIA were worth $107,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC boosted its position in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 130 shares during the period. AllSquare Wealth Management LLC bought a new position in shares of IQVIA in the first quarter valued at approximately $33,000. Trust Co. of Toledo NA OH bought a new position in shares of IQVIA in the second quarter valued at approximately $39,000. Finally, Larson Financial Group LLC raised its stake in IQVIA by 109.9% in the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 144 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Down 2.3%

Shares of IQVIA stock opened at $198.35 on Monday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $237.34. The stock has a market capitalization of $33.72 billion, a price-to-earnings ratio of 28.70, a P/E/G ratio of 2.18 and a beta of 1.32. The company’s 50 day moving average price is $189.02 and its 200-day moving average price is $168.11.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion for the quarter, compared to analysts’ expectations of $3.96 billion. During the same quarter last year, the business earned $2.64 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

IQV has been the topic of a number of recent analyst reports. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their target price for the company from $195.00 to $235.00 in a research note on Thursday. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Truist Financial raised their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. Finally, Evercore ISI raised their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $236.45.

Insider Activity at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.